Assessment of clinical profile of coronary artery disease in Indian Population

Size: px
Start display at page:

Download "Assessment of clinical profile of coronary artery disease in Indian Population"

Transcription

1 Original article: Assessment of clinical profile of coronary artery disease in Indian Population 1Dr J S Dhadwad, 2 Dr N G Karandikar 1 Assistant Professor, Department of Medicine, P. Dr. D Y Patil Medical College, Pimpri, Pune, India 2 Professor, Department of Medicine, B J Medical College, Pune, India Corresponding author: Dr J S Dhadwad Abstract: Introduction: Coronary artery disease is worldwide one of the important mortality associated cause. The present study was done for assessment of clinical profile in coronary artery disease in Indian Population. Material & methods: In present study 50 patients of coronary artery disease who have undergone coronary angiography where selected for over a period of Dec.2003 to may 2005 with reference to clinical profile and lipid profile. Various associated factors were assessed and correlated statistically. Observations and results: In our present study we found that, 42% patients in this study were smoker (smokes 5-8 cigarettes/day since years) Percentage of non smoker is more in this study group i.e. 58%. Other risk factor (Tobacco addition / Alcoholism / raised homocystine / postmenopausal age). And hypertensions are the major risk factors in this study. In this study 92% of patients having chest pain major symptoms of CHD Conclusion: Smoking and alcoholism found major etiological factors associated with CHD. Introduction Coronary artery disease is worldwide one of the important mortality associated cause. Postprandial lipemia, characterized by a rise in triglycerides rich lipoproteins after eating, is a dynamic, nonsteady--- state condition in which humans spends the majority of time. There are several lines of evidence suggesting that postprandial lipemia increases the risk of atherogenesis. 1,2 Clinical data show a correlation between postprandial lipoproteins and the presence/progression of coronary artery disease. Number of factors is associated with coronary artery disease. In the present study, we tried to evaluate various etiological factors associated with coronary artery disease in Indian Population. 3 Material & methods: In present study 50 patients of coronary artery disease who have undergone coronary angiography where selected for over a period of Dec.2003 to may 2005 with reference to clinical profile and lipid profile. Inclusion Criteria: All patients of coronary artery disease who have undergone coronary angiography irrespective of their age and sex. Exclusion Criteria: Hepatic dysfunction Acute & chronic pancreatitis Deranged renal function Congenital heart disease (CHD) Diabetics moieties on insulin Uncontrolled HT 117

2 The information was collected from patient history and from OPD papers. The collected Observations The present study of 50 patient of coronary artery disease who undergone coronary information was tabulated and statistical analysis was done using appropriate measures. angiography with special preference to postprandial lipemia. Table 1 Age and sex distribution ( n=50) Age group Male Female Total percentage % % % > % Total % Table No. 2 Smoking ( n=50) Class No. of patients percentage Smoker 21 42% Non smoker 29 58% Total % 42% patients in this study were smoker (smokes 5-8 cigarettes/day since years) Percentage of non smoker is more in this study group i.e. 58% Table No. 3 Other risk factor percentage Risk factors No. of patients percentage BMI> % Hypertension 18 36% Diabetes mellitus 12 24% Family history 11 22% Other risk factors 24 48% Other risk factor (Tobacco addition / Alcoholism / raised homocystine / postmenopausal age). And hypertensions are the major risk factors in this study

3 Table No. 4 No. of risk factor (n=50) No. of risk factors No. of patients percentage No risk factor 04 8% One risk factor 15 30% Two risk factor 18 36% 3 or more risk factor 13 26% Table No. 5 Symptomatology (clinical profile) Symptoms No. of patients percentage Chest pain 46 92% Perspiration 31 62% Palpitation 13 26% Syncope 13 26% Nausea and vomiting 11 22% Abdominal pain 10 20% Dyspnoea 24 48% In this study 92% of patients having chest pain major symptoms of CHD. Discussion have adverse effect on endothelium and can In our present study we found that, 42% patients penetrate into the sub endothelial space. in this study were smoker (smokes 5-8 Exchange of core lipids between postprandial cigarettes/day since years) Percentage of lipoproteins and low density lipoprotein (LDL)/ non smoker is more in this study group i.e. 58%. high density lipoproteins (HDL) increased Other risk factor (Tobacco addition / Alcoholism during prolonged lipemia, resulting in small, / raised homocystine / postmenopausal age). And dense, LDL particles and reduced HDL hypertensions are the major risk factors in this cholesterol levels. Hemostatic variables, study. In this study 92% of patients having chest including clotting factors, platelet reactivity and pain major symptoms of CHD. 4 monocyte cytokine expression, may be increased There are several lines of evidence suggesting during p postprandial lipemia. 5 that postprandial lipemia increases the risk of In the present study, we evaluated the variation atherogenesis. Clinical data show a correlation of triglycerides postprandially in respect to between postprandial lipoproteins and the serum HDL cholesterol levels in patients of presence/progression of coronary artery disease. coronary artery disease who undergone coronary Mechanistic studies demonstrate that angiography. This delayed TH clearance triglycerides rich lipoprotein remnants may

4 postprandially seems to result in low HDL cholesterol even in subjects with low fasting TG. Definition of abnormal postprandial lipemia postprandial hypertriglyceridemia as any postprandial TG concentration (at 4.6 or 8 hours) higher than the highest TG concentration in any hour in any control individual. This TG value was 219mg%. The present study of 50 patient was indented to evaluate risk factors associated with coronary artery disease, clinical profile, lipid profile and relation between coronary angiography profile and lipid profile. In present study 84% of patient were ages of 40 years and above. Only 8% between year, 4% between years and year. This is an agreement with other study conducted by Gohlke et al have shown the incidence tobe 67% in age group and 8% below 30 year age. 6 PK Biswas et al showed that 9.7% of patients in age group year while 90.3% belong to 3l- 40 year of age.kc Garg et al observed that out of 60 cases of aged 40 years and below were 20(33.3%) while of age 40 and above was 40 (66.6%). 7 Even among the female both in our study are above 40 years of the age. The finding in present study are comparable to above studies which indicates that coronary artery disease is common after the age of 40 years. In present study 50 patient of coronary artery disease out of which 4l(82%) were male, 9(l8%) were female. This is an agreement with 92% male affection has shown by Glover et al. In the present study it was found that 2l (40%) out of 50 were smoker and 29(58%) were nonsmoker. This is in agreement with other study (Bansal l978 (76%), Yavagal l989, 75%%. 8,9 Conclusion: Smoking and alcohol found important etiological factors in this study. References: 1. Abrems JJ, Grundy SM, Ginsberg H. Metabolism of Plasma TG in Hypothyroitism and hpertthyroidism in man. J Lipid Res. 1981;22; Autin MA, Brunzell J.D., Fitch WL, Krauss RM, Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia. Athorosclorosis ;10; Axelson M, Eliasson B, Joheim E, Lenner RA, Taskinon MR, Smith U. Lipid intolerance in smokers. J. Intern. Med. 1995;237; Dianne C. Hyson PHD, John C. Routlodge MD, and Lars Berglund MD PHD, Current Authorosclerosis Repaort 2003, 5: Genovofa D. Kibvou, Katherine K. Anagnostopoulou, Noktaros Pilatis, Nikolaos, Kafaltis, Konstandine, Sordila, Elteherios Psarro and Dennis V. Cokkinos, Lo fasting low high density lipoprotein and pastprandial lipemia, Lipids in Health & Disease 2004, 3: Glover AV, Kuber M.T., Warren S.E., Vieweg WVR, Myocardial infarction before age 36: Risk factor and artiographic analysis. Am. J. of Cardiol, 49,

5 7. P.K. Biswas et al, Risk factors and angiographic profile of CAD in young, JIMA Vol. 93, No. 3, March Patsch J.R., G. Miesenbock, T. Hopferwieser, V. Muhlberger, E. Knapp, J.K. Dunn, A.M. Gotto Jr., W. Patsch Relation of tringlyceride metabolism & coronary artery disease studies in postprandial state. Arteroscler Thromb 12: Yudkin JS, Stehouwar CD, Emesis JJ et al. Creactive protein in healthy subjects : association with obesity insulin resistance and entothetial fysfunction : a potential role of cytokines vilography. 199;19:

Pathophysiology of Lipid Disorders

Pathophysiology of Lipid Disorders Pathophysiology of Lipid Disorders Henry Ginsberg, M.D. Division of Preventive Medicine and Nutrition CHD in the United States CHD is the single largest killer of men and women 12 million have history

More information

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD

Part 1 Risk Factors and Atherosclerosis. LO1. Define the Different Forms of CVD Week 3: Cardiovascular Disease Learning Outcomes: 1. Define the difference forms of CVD 2. Describe the various risk factors of CVD 3. Describe atherosclerosis and its stages 4. Describe the role of oxidation,

More information

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries

2.5% of all deaths globally each year. 7th leading cause of death by % of people with diabetes live in low and middle income countries Lipid Disorders in Diabetes (Diabetic Dyslipidemia) Khosrow Adeli PhD, FCACB, DABCC Head and Professor, Clinical Biochemistry, The Hospital for Sick Children, University it of Toronto Diabetes A Global

More information

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID?

Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Update On Diabetic Dyslipidemia: Who Should Be Treated With A Fibrate After ACCORD-LIPID? Karen Aspry, MD, MS, ABCL, FACC Assistant Clinical Professor of Medicine Warren Alpert Medical School of Brown

More information

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease

Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Original article: Study of serum Lipid Profile patterns of Indian population in young Ischaemic Heart Disease Dr Sonu Yadav, Dr Abhijit Nikam, Dr Vivek Chiddarwar, Dr A L Kakrani Department of Medicine,

More information

Chapter (5) Etiology of Low HDL- Cholesterol

Chapter (5) Etiology of Low HDL- Cholesterol Chapter (5) Etiology of Low HDL- Cholesterol The aim of this chapter is to summarize the different etiological factors mainly the role of life-style and different disease conditions contributing to the

More information

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium

Comprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:

More information

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases

Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Original article: Study of relationship of serum Lipid Profile and etiological factors of Ischaemic Heart Diseases Dr Abhijit Nikam, Dr Sonu Yadav, Dr Vivek Chiddarwar, Dr A L Kakrani Dept of Medicine,

More information

It is currently estimated that diabetes prevalence by

It is currently estimated that diabetes prevalence by clinical Study The Prevalence and Pattern of Dyslipidemia among Type 2 Diabetic Patients at Rural Based Hospital in Gujarat, India Hetal Pandya*, JD Lakhani**, J Dadhania, A Trivedi Abstract Only proper

More information

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus

A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Type 2 Diabetis Mellitus Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/21 A Study to Show Postprandial Hypertriglyceridemia as a Risk Factor for Macrovascular Complications in Bingi Srinivas

More information

Cardiovascular Complications of Diabetes

Cardiovascular Complications of Diabetes VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary

More information

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden

Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD

More information

Total risk management of Cardiovascular diseases Nobuhiro Yamada

Total risk management of Cardiovascular diseases Nobuhiro Yamada Nobuhiro Yamada The worldwide burden of cardiovascular diseases (WHO) To prevent cardiovascular diseases Beyond LDL Multiple risk factors With common molecular basis The Current Burden of CVD CVD is responsible

More information

A STUDY OF FASTING AND POSTPRANDIAL LIPID ABNORMALITIES IN TYPE 2 DIABETES MELLITUS

A STUDY OF FASTING AND POSTPRANDIAL LIPID ABNORMALITIES IN TYPE 2 DIABETES MELLITUS A STUDY OF FASTING AND POSTPRANDIAL LIPID ABNORMALITIES IN TYPE 2 DIABETES MELLITUS Babu R 1, Shigil Mathew Varghese 2, Seetha Ramireddy M 3, Arun Kumar S 4, Ramesh Bala A 5 1Assistant Professor and Registrar,

More information

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date

Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Original Policy Date MP 2.04.22 Measurement of Serum Intermediate Density Lipoproteins (Remnant-like Particles) Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with

More information

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION

EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT Submitted to UNIVERSITY GRANTS COMMISSION 1 A STUDY ON THE EFFECT OF DIET & LIFE STYLE ON THE INCIDENCE OF CORONARY ARTERY DISEASE IN MODERATELY DRINKING EX MILITARY MEN IN PATHANAMTHITTA DISTRICT. EXECUTIVE SUMMARY OF THE MINOR RESEARCH PROJECT

More information

Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes

Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/359 Clinical Study of Lipid Profile Pattern in Acute Coronary Syndromes V Suresh Kumar, Madavaram Sreelatha Assistant

More information

The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)

The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) The Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) Recruitment The majority of participants in the GOLDN Study were re-recruited from threegenerational pedigrees from two National Heart, Lung

More information

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk

The New Gold Standard for Lipoprotein Analysis. Advanced Testing for Cardiovascular Risk The New Gold Standard for Lipoprotein Analysis Advanced Testing for Cardiovascular Risk Evolution of Lipoprotein Testing The Lipid Panel Total Cholesterol = VLDL + LDL + HDL Evolution of Lipoprotein Testing

More information

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk

The Metabolic Syndrome Update The Metabolic Syndrome Update. Global Cardiometabolic Risk The Metabolic Syndrome Update 2018 Marc Cornier, M.D. Professor of Medicine Division of Endocrinology, Metabolism & Diabetes Anschutz Health and Wellness Center University of Colorado School of Medicine

More information

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both

Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Low-density lipoprotein as the key factor in atherogenesis too high, too long, or both Lluís Masana Vascular Medicine and Metabolism Unit. Sant Joan University Hospital. IISPV. CIBERDEM Rovira i Virgili

More information

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah

Metabolic Syndrome. Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Metabolic Syndrome Bill Roberts, M.D., Ph.D. Professor of Pathology University of Utah Objectives Be able to outline the pathophysiology of the metabolic syndrome Be able to list diagnostic criteria for

More information

Postprandial Dyslipidemia as a Screening Tool for Risk Stratification of Acute Coronary Syndrome in Type 2 Diabetes Mellitus

Postprandial Dyslipidemia as a Screening Tool for Risk Stratification of Acute Coronary Syndrome in Type 2 Diabetes Mellitus IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 2 Ver. 10 February. (2018), PP 16-20 www.iosrjournals.org Postprandial Dyslipidemia as a Screening

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research   ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Diabetic Dyslipidemia Insulin Resistance May Be One of the Causes of Mahendra D. Bikkad, Suresh

More information

Metabolism and Atherogenic Properties of LDL

Metabolism and Atherogenic Properties of LDL Metabolism and Atherogenic Properties of LDL Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy & Affiliate Associate Professor of Internal

More information

Clinical and Etiological Profile of Acute Myocardial Infarction in Young

Clinical and Etiological Profile of Acute Myocardial Infarction in Young International Journal of Scientific and Research Publications, Volume 5, Issue 4, April 2015 1 Clinical and Etiological Profile of Acute Myocardial Infarction in Young Dr. M. Bhargavi Devi, M.D * ; Dr.S.

More information

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?

There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,

More information

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL

Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:

More information

JMSCR Vol 05 Issue 05 Page May 2017

JMSCR Vol 05 Issue 05 Page May 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i5.193 Lipid Profile as Early Predictor of Complication

More information

Risk Factors for Heart Disease

Risk Factors for Heart Disease Risk Factors for Heart Disease Risk Factors we cannot change (Age, Gender, Family History) Risk Factors we can change (modifiable) Smoking Blood pressure Cholesterol Diabetes Inactivity Overweight Stress

More information

Life Science Journal 2018;15(12)

Life Science Journal 2018;15(12) Multicenter observational study of risk factors profile in a sample of Egyptian Patients with Acute Coronary Syndrome (part of Egyptian Cardiovascular Risk Factors Project) Prof. Dr. Ahmed Ashraf Reda,

More information

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus

A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Original Research Article A comparative study on the fasting and post prandial lipid levels as a cardiovascular risk factor in patients with type 2 diabetes mellitus Deepa Kalikavil Puthenveedu 1, Sundaraj

More information

Lipoprotein Particle Profile

Lipoprotein Particle Profile Lipoprotein Particle Profile 50% of people at risk for HEART DISEASE are not identified by routine testing. Why is LPP Testing The Most Comprehensive Risk Assessment? u Provides much more accurate cardiovascular

More information

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING

REAGENTS. RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING REAGENTS RANDOX sdldl CHOLESTEROL (sdldl-c) SIZE MATTERS: THE TRUE WEIGHT OF RISK IN LIPID PROFILING Randox sdldl Cholesterol (sdldl-c) Size Matters: The True Wight of Risk in Lipid Profiling 1. BACKGROUND

More information

To Study the Association of Coronary Artery Disease and Non Alcoholic Fatty Liver Disease

To Study the Association of Coronary Artery Disease and Non Alcoholic Fatty Liver Disease International Journal of Current Research in Medical Sciences ISSN: 2454-5716 P-ISJN: A4372-3064, E -ISJN: A4372-3061 www.ijcrims.com Original Research Article Volume 3, Issue 11-2017 To Study the Association

More information

Chapter 18. Diet and Health

Chapter 18. Diet and Health Chapter 18 Diet and Health Risk Factors and Chronic Diseases Interrelationships among Chronic Diseases Chronic Disease Heart Disease and Stroke Hypertension Cancer Diabetes The Formation of Plaques in

More information

Women and Heart Disease

Women and Heart Disease Women and Heart Disease The Very Latest in Cardiovascular Medicine and Surgery Gretchen L. Wells, MD, PhD, FACC Thomas Whayne Endowed Professor in Women s Heart Health Gill Heart Institute University of

More information

Tracking a Killer Molecule

Tracking a Killer Molecule Tracking a Killer Molecule Mercodia Oxidized LDL ELISA www.mercodia.com Mercodia Oxidized LDL ELISA products Product Catalog No Kit size Oxidized LDL ELISA 10-1143-01 96 wells Oxidized LDL competitive

More information

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY MCC-006 POST GRADUATE DIPLOMA IN CLINICAL CARDIOLOGY (PGDCC) 00269 Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY Time : 2 hours Maximum Marks : 60 Note : There will be multiple

More information

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups

A: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were

More information

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD

Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Role of apolipoprotein B-containing lipoproteins in the development of atherosclerosis Jan Borén MD, PhD Our laboratory focuses on the role of apolipoprotein (apo) B- containing lipoproteins in normal

More information

Fibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit

Fibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.

More information

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug: 2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:

More information

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers

KEY COMPONENTS. Metabolic Risk Cardiovascular Risk Vascular Inflammation Markers CardioMetabolic Risk Poor blood sugar regulation and unhealthy triglyceride and lipoprotein levels often present long before the diagnosis of type 2 Diabetes. SpectraCell s CardioMetabolic and Pre-Diabetes

More information

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017

Disclosures. Background 1 What is Known MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES. Background 2 What is Not Known 10/2/2017 Disclosures MENOPAUSE, ESTROGENS, AND LIPOPROTEIN PARTICLES Grants: NIH, Quest Diagnostics Consultant: Quest Diagnostics Merck Global Atherosclerosis Advisory Board Ronald M. Krauss, Children s Hospital

More information

MOLINA HEALTHCARE OF CALIFORNIA

MOLINA HEALTHCARE OF CALIFORNIA MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel

More information

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines

New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines Clin. Cardiol. Vol. 26 (Suppl. III), III-19 III-24 (2003) New Features of the National Cholesterol Education Program Adult Treatment Panel III Lipid-Lowering Guidelines H. BRYAN BREWER, JR, M.D. Molecular

More information

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University

Andrejs Kalvelis 1, MD, PhD, Inga Stukena 2, MD, Guntis Bahs 3 MD, PhD & Aivars Lejnieks 4, MD, PhD ABSTRACT INTRODUCTION. Riga Stradins University CARDIOVASCULAR RISK FACTORS ORIGINAL ARTICLE Do We Correctly Assess the Risk of Cardiovascular Disease? Characteristics of Risk Factors for Cardiovascular Disease Depending on the Sex and Age of Patients

More information

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study

Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Small dense low-density lipoprotein is a risk for coronary artery disease in an urban Japanese cohort: The Suita study Hidenori Arai 1, Yoshihiro Kokubo 2, Makoto Watanabe 2, Tatsuya Sawamura 3, Tomonori

More information

Lipid profile in Diabetes Mellitus

Lipid profile in Diabetes Mellitus Original Research Shankarprasad DS 1,*, Shivanand Gundalli 2, Mahantesh B 3, SV Kashinakunti 4, Sunitha P 5 1,4 Professor, 3 Postgradute student, 5 Associate Professor, Department of Biochemistry, 2 Assistant

More information

Asia Pacific Journal of Research ISSN (Print) : ISSN (Online) :

Asia Pacific Journal of Research ISSN (Print) : ISSN (Online) : Study of Post Prandial Hypertriglyceridemia and Glycosylated Hemoglobin and its co relation with Carotid Intima Media Thickness in Patients with Type 2 Diabetes Mellitus DR. SHASHIDHAR. G. MD MEDICINE

More information

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia

PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,

More information

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension

Plasma fibrinogen level, BMI and lipid profile in type 2 diabetes mellitus with hypertension World Journal of Pharmaceutical Sciences ISSN (Print): 2321-3310; ISSN (Online): 2321-3086 Published by Atom and Cell Publishers All Rights Reserved Available online at: http://www.wjpsonline.org/ Original

More information

Lipids Testing

Lipids Testing Previously Listed as Edit 12 190.23 - Lipids Testing Lipoproteins are a class of heterogeneous particles of varying sizes and densities containing lipid and protein. These lipoproteins include cholesterol

More information

Title for Paragraph Format Slide

Title for Paragraph Format Slide Title for Paragraph Format Slide Presentation Title: Month Date, Year Atherosclerosis A Spectrum of Disease: February 12, 2015 Richard Cameron Padgett, MD Executive Medical Director, OHVI Pt RB Age 38

More information

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015

Complications of Diabetes mellitus. Dr Bill Young 16 March 2015 Complications of Diabetes mellitus Dr Bill Young 16 March 2015 Complications of diabetes Multi-organ involvement 2 The extent of diabetes complications At diagnosis as many as 50% of patients may have

More information

Metabolic Syndrome.

Metabolic Syndrome. www.bmiweightloss.com.au What is the metabolic syndrome? The was first described in 1988 by Gerald Reavson It was originally described as the clustering of four conditions These conditions when present

More information

Approach to Dyslipidemia among diabetic patients

Approach to Dyslipidemia among diabetic patients Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences

More information

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease

ORIGINAL INVESTIGATION. Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease ORIGINAL INVESTIGATION Relation of Triglyceride Levels, Fasting and Nonfasting, to Fatal and Nonfatal Coronary Heart Disease Lynn E. Eberly, PhD; Jeremiah Stamler, MD; James D. Neaton, PhD; for the Multiple

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009

The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain

More information

Gemfibrozil Improves Postprandial Hypertriglyceridemia in Patients with Isolated Low HDL

Gemfibrozil Improves Postprandial Hypertriglyceridemia in Patients with Isolated Low HDL Lipid Insights Original Research Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Gemfibrozil Improves Postprandial Hypertriglyceridemia in Patients with Isolated

More information

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease

Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AMERICAN COLLEGE OF ENDOCRINOLOGY Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease Writing Committee Chair: Paul S. Jellinger,

More information

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS

THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS THE CLINICAL BIOCHEMISTRY OF LIPID DISORDERS Hormonal regulation INSULIN lipid synthesis, lipolysis CORTISOL lipolysis GLUCAGON lipolysis GROWTH HORMONE lipolysis CATECHOLAMINES lipolysis LEPTIN catabolism

More information

Lipid/Lipoprotein Structure and Metabolism (Overview)

Lipid/Lipoprotein Structure and Metabolism (Overview) Lipid/Lipoprotein Structure and Metabolism (Overview) Philip Barter President, International Atherosclerosis Society Centre for Vascular Research University of New South Wales Sydney, Australia Disclosures

More information

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES

THE EFFECT OF VITAMIN-C THERAPY ON HYPERGLYCEMIA, HYPERLIPIDEMIA AND NON HIGH DENSITY LIPOPROTEIN LEVEL IN TYPE 2 DIABETES Int. J. LifeSc. Bt & Pharm. Res. 2013 Varikasuvu Seshadri Reddy et al., 2013 Review Article ISSN 2250-3137 www.ijlbpr.com Vol. 2, No. 1, January 2013 2013 IJLBPR. All Rights Reserved THE EFFECT OF VITAMIN-C

More information

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002

Hypertriglyceridemia. Ara Metjian, M.D. Resident s Report 20 December 2002 Hypertriglyceridemia Ara Metjian, M.D. Resident s Report 20 December 2002 Review of Lipids Chylomicrons (CM): Dietary lipids absorbed through the GI tract are assembled intracellularly into CM. Very Low

More information

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital

Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital 1. Importance of Lowering LDL-Cholesterol in Diabetes Patients & Lipid Guidelines Prevalence of dyslipidemia in Korea Prevalence

More information

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center

Diabetes and Heart Disease. Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center Diabetes and Heart Disease Sarah Alexander, MD, FACC Assistant Professor of Medicine Rush University Medical Center No conflicts of interest or financial relationships to disclose. 2 What s the problem??

More information

Nature Genetics: doi: /ng.3561

Nature Genetics: doi: /ng.3561 Supplementary Figure 1 Pedigrees of families with APOB p.gln725* mutation and APOB p.gly1829glufs8 mutation (a,b) Pedigrees of families with APOB p.gln725* mutation. (c) Pedigree of family with APOB p.gly1829glufs8

More information

Know Your Number Aggregate Report Single Analysis Compared to National Averages

Know Your Number Aggregate Report Single Analysis Compared to National Averages Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics

More information

The Gender Divide Women, Men and Heart Disease February 2017

The Gender Divide Women, Men and Heart Disease February 2017 The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Arteriosclerosis & Atherosclerosis

Arteriosclerosis & Atherosclerosis Arteriosclerosis & Atherosclerosis Arteriosclerosis = hardening of arteries = arterial wall thickening + loss of elasticity 3 types: -Arteriolosclerosis -Monckeberg medial sclerosis -Atherosclerosis Arteriosclerosis,

More information

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic

CVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This

More information

Cardiovascular System and Health. Chapter 15

Cardiovascular System and Health. Chapter 15 Cardiovascular System and Health Chapter 15 Cardiovascular Disease Leading cause of death in U.S. Claims 1 life every 43 seconds Often, the first sign is a fatal heart attack Death Rates #1 CVD #2 Cancer

More information

Comparison of Fasting and Postprandial Lipid Profile in Patients of Coronary Heart Disease

Comparison of Fasting and Postprandial Lipid Profile in Patients of Coronary Heart Disease Comparison of Fasting and Postprandial Lipid Profile in Patients of Coronary Heart Disease Vijay Shankar*, Harnam Kaur**, Kiran Dahiya***, MS Gupta**** Abstract Lipid profile and blood glucose were estimated

More information

Although medical advances have curbed

Although medical advances have curbed PREVENTION OF CORONARY HEART DISEASE IN THE METABOLIC SYNDROME AND DIABETES MELLITUS * Sherita Hill Golden, MD, MHS ABSTRACT The leading cause of death in patients with diabetes is cardiovascular disease.

More information

Clinical profile, risk factors and outcome of ischemic heart disease patients at tertiary care centre

Clinical profile, risk factors and outcome of ischemic heart disease patients at tertiary care centre International Journal of Advances in Medicine http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20183434 Clinical profile,

More information

Welcome and Introduction

Welcome and Introduction Welcome and Introduction This presentation will: Define obesity, prediabetes, and diabetes Discuss the diagnoses and management of obesity, prediabetes, and diabetes Explain the early risk factors for

More information

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution

Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution Figure S1. Comparison of fasting plasma lipoprotein levels between males (n=108) and females (n=130). Box plots represent the quartiles distribution of A: total cholesterol (TC); B: low-density lipoprotein

More information

IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW

IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW IMPORTANCE OF HIGH TRIGLYCERIDES AS A CARDIOVASCULAR RISK FACTOR IN INDIAN DIABETIC POPULATION A REVIEW Hiren Pandya Department of Medicine, AMC MET Medical College, Ahmedabad, Gujarat, India Correspondence

More information

Normal blood vessels A= artery V= vein

Normal blood vessels A= artery V= vein Normal blood vessels A= artery V= vein Artery (A) versus vein (V) ARTERIOSCLEROSIS Arteriosclerosis ="hardening of the arteries" arterial wall thickening and loss of elasticity. Three patterns are recognized,

More information

DECLARATION OF CONFLICT OF INTEREST. None

DECLARATION OF CONFLICT OF INTEREST. None DECLARATION OF CONFLICT OF INTEREST None BURDEN OF CORONARY ARTERY DISEASE IN DIABETES IN INDIA Amal Kumar Banerjee MD, DM,FACC,FESC,FACP,FAPSC,FICC President Association of Physicians of India SAARC Cardiac

More information

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC

Hypertriglyceridemia: Why, When, and How to Treat. Gregory Cohn, MD, FNLA, FASPC Hypertriglyceridemia: Why, When, and How to Treat Gregory Cohn, MD, FNLA, FASPC DISCLOSURES Consultant to Akcea Therapeutics (in the past 12 months). OUTLINE I. Lipoproteins II. Non-HDL-C III. Causes and

More information

Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease

Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease www.jmscr.igmpublication.org Impact Factor 1.1147 ISSN (e)-2347-176x Status of Small Dense LDL in Fasting and Nonfasting Lipidemia in Coronary Heart Disease Authors Pranshi Mishra¹, Neelima Singh²,Puneet

More information

Original Research Article

Original Research Article A STUDY TO ESTIMATE SUBCLINICAL ATHEROSCLEROSIS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS BY MEASURING THE CAROTID INTIMAL MEDIAL THICKNESS Natarajan Kandasamy 1, Rajan Ganesan 2, Thilakavathi Rajendiran

More information

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones?

1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 1Why lipids cannot be transported in blood alone? 2How we transport Fatty acids and steroid hormones? 3How are dietary lipids transported? 4How lipids synthesized in the liver are transported? 5 Lipoprotien

More information

Feeding Effect of Terminalia Arjuna and Guggul on the Biophysical Symptoms of Dyslipidemic Patients Jain Bharti 1,Pathak Sakshi 2 and Yadav Shubha 3

Feeding Effect of Terminalia Arjuna and Guggul on the Biophysical Symptoms of Dyslipidemic Patients Jain Bharti 1,Pathak Sakshi 2 and Yadav Shubha 3 Feeding Effect of Terminalia Arjuna and Guggul on the Biophysical Symptoms of Dyslipidemic Patients Jain Bharti 1,Pathak Sakshi 2 and Yadav Shubha 3 1. Professor, Department of Food Science and Nutrition

More information

Section Editor Mason W Freeman, MD

Section Editor Mason W Freeman, MD Official reprint from UpToDate www.uptodate.com 2015 UpToDate The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek

More information

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role

More information

5/28/2010. Pre Test Question

5/28/2010. Pre Test Question Myth of Metabolic Syndrome? C. W. Spellman, DO, PhD Professor and Associate Dean Research Dir. Center Diabetes and Metabolic Disorders Department Internal Medicine, Div. Endocrinology Texas Tech University

More information

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants

!!! Aggregate Report Fasting Biometric Screening CLIENT!XXXX. May 2, ,000 participants Aggregate Report Fasting Biometric Screening CLIENTXXXX May 2, 2014 21,000 participants Contact:404.636.9437~Website:www.atlantahealthsys.com RISK FACTOR QUESTIONNAIRE Participants Percent Do not exercise

More information

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS

ATP III (Adult Treatment Panel III) CLASSIFICATION C IN ADULTS LABORATORY AND RISK FACTORS OF ATHEROSCLEROSIS S R. Mohammadi Biochemist (Ph.D.) Faculty member of Medical Faculty RISK FACTORS FOR CHD Clinical Risk Factors Laboratory Risk Factors MAJOR CLINICAL RISK

More information

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives

What Else Do You Need to Know? Presenter Disclosure Information. Case 1: Cardiovascular Risk Assessment in a 53-Year-Old Man. Learning Objectives 9: 1:am Understanding Dyslipidemia Testing and Screening: Importance of Lipoprotein Particle Analysis SPEAKER Matthew Sorrentino, MD, FACC Presenter Disclosure Information The following relationships exist

More information

Latest Guidelines for Lipid Management

Latest Guidelines for Lipid Management Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline

More information

Women and Heart Disease : Separating Fact from Fiction

Women and Heart Disease : Separating Fact from Fiction Women and Heart Disease : Separating Fact from Fiction Maria T. Vivaldi M.D. Director of Education MGH Women s Heart Health Program Corrigan Minehan Heart Center Women and Heart Disease : Separating Fact

More information

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017

Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Non-fasting Lipid Profile Getting to the Heart of the Matter! Medimail Dec 2017 Historical Basis for Fasting Lipids The initial classifications of hyperlipidemia proposed in 1967 were genetic and required

More information

Role of dyslipidaemia in cardiovascular diseases and the therapeutic benefits by the appropriate drugs Banoo H

Role of dyslipidaemia in cardiovascular diseases and the therapeutic benefits by the appropriate drugs Banoo H Role of dyslipidaemia in cardiovascular diseases and the therapeutic benefits by the appropriate drugs Banoo H Introduction Coronary artery disease is an important cause of mortality and mor- bidity in

More information

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD

Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Metabolism, Atherogenic Properties and Agents to reduce Triglyceride-Rich Lipoproteins Manfredi Rizzo, MD, PhD Associate Professor of Internal Medicine Faculty of Medicine, University of Palermo, Italy

More information